Voyager Therapeutics Inc (NASDAQ:VYGR)’s share price traded down 5.3% during trading on Thursday . The company traded as low as $25.65 and last traded at $25.86. 789,715 shares traded hands during mid-day trading, an increase of 119% from the average session volume of 361,239 shares. The stock had previously closed at $27.32.
Several equities analysts recently issued reports on VYGR shares. BidaskClub upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. Canaccord Genuity reissued a “buy” rating and issued a $26.00 target price on shares of Voyager Therapeutics in a report on Tuesday, January 23rd. Cowen reissued a “buy” rating on shares of Voyager Therapeutics in a report on Tuesday, October 31st. ValuEngine downgraded Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $28.00 target price on shares of Voyager Therapeutics in a report on Tuesday, November 28th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and thirteen have issued a buy rating to the company. Voyager Therapeutics currently has an average rating of “Buy” and an average target price of $28.27.
The firm has a market cap of $813.28, a price-to-earnings ratio of -10.12 and a beta of 4.04.
In other Voyager Therapeutics news, insider Bernard Ravina sold 5,490 shares of the company’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $13.63, for a total transaction of $74,828.70. Following the completion of the sale, the insider now owns 10,983 shares in the company, valued at approximately $149,698.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 11,571 shares of company stock valued at $179,067 in the last quarter. Corporate insiders own 8.00% of the company’s stock.
Several institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN increased its position in shares of Voyager Therapeutics by 312.8% in the 3rd quarter. Wells Fargo & Company MN now owns 377,190 shares of the company’s stock valued at $7,766,000 after buying an additional 285,806 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Voyager Therapeutics by 20.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 53,225 shares of the company’s stock worth $477,000 after buying an additional 9,207 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Voyager Therapeutics by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock worth $3,860,000 after buying an additional 13,194 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of Voyager Therapeutics during the 3rd quarter worth about $5,155,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of Voyager Therapeutics during the 3rd quarter worth about $2,695,000. Institutional investors own 70.52% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.thelincolnianonline.com/2018/02/24/voyager-therapeutics-vygr-shares-down-5-3.html.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.